December 8, 2025BloodOpen Access

Comparison of hemosil and innovance antithrombin assays using Hemophilia A plasma and antithrombin lowering (to mimic fitusiran)

View Full Paper

Ask AI

Bookmark

The INNOVANCE assay shows higher antithrombin activity compared to HemoSIL at lower AT levels below 25%.
Statistical analysis demonstrated significant differences at lower target AT levels, particularly at 15% and 10%.
Observational analysis of hemophilia A plasma samples revealed that both assays maintain concordance at higher AT levels (≥50%).
Clinicians should interpret antithrombin results cautiously with specific assays to ensure proper fitusiran dosing.

Discussion

No takes yet. Share an insight, caveat, or question.

Comparison of antithrombin assays reveals discrepancies in hemophilia A monitoring, indicating potential dosing inaccuracies with fitusiran.

Casas et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Comparison of antithrombin assays reveals discrepancies in hemophilia A monitoring, indicating potential dosing inaccuracies with fitusiran.